197 related articles for article (PubMed ID: 31431371)
1. Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy.
Klement RJ; Sonke JJ; Allgäuer M; Andratschke N; Appold S; Belderbos J; Belka C; Dieckmann K; Eich HT; Flentje M; Grills I; Eble M; Hope A; Grosu AL; Semrau S; Sweeney RA; Hörner-Rieber J; Werner-Wasik M; Engenhart-Cabillic R; Ye H; Guckenberger M
Radiother Oncol; 2020 Jan; 142():210-216. PubMed ID: 31431371
[TBL] [Abstract][Full Text] [Related]
2. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
4. Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?
Santiago A; Barczyk S; Jelen U; Engenhart-Cabillic R; Wittig A
Radiat Oncol; 2016 May; 11():67. PubMed ID: 27154064
[TBL] [Abstract][Full Text] [Related]
5. Revisiting the formalism of equivalent uniform dose based on the linear-quadratic and universal survival curve models in high-dose stereotactic body radiotherapy.
Chan MKH; Chiang CL
Strahlenther Onkol; 2021 Jul; 197(7):622-632. PubMed ID: 33245378
[TBL] [Abstract][Full Text] [Related]
6. Optimal dose and fraction number in SBRT of lung tumours: A radiobiological analysis.
Ruggieri R; Stavrev P; Naccarato S; Stavreva N; Alongi F; Nahum AE
Phys Med; 2017 Dec; 44():188-195. PubMed ID: 28130055
[TBL] [Abstract][Full Text] [Related]
7. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
[TBL] [Abstract][Full Text] [Related]
8. Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
Lee P; Loo BW; Biswas T; Ding GX; El Naqa IM; Jackson A; Kong FM; LaCouture T; Miften M; Solberg T; Tome WA; Tai A; Yorke E; Li XA
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):160-171. PubMed ID: 30954520
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy for stage I non-small cell lung cancer: The importance of treatment planning algorithm and evaluation of a tumor control probability model.
Ohri N; Tomé W; Kalnicki S; Garg M
Pract Radiat Oncol; 2018; 8(2):e33-e39. PubMed ID: 29233523
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy.
Duijm M; van der Voort van Zyp NC; Granton PV; van de Vaart P; Mast ME; Oomen-de Hoop E; Hoogeman MS; Nuyttens JJ
Acta Oncol; 2020 Jul; 59(7):809-817. PubMed ID: 32286140
[No Abstract] [Full Text] [Related]
12. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.
Haque W; Verma V; Polamraju P; Farach A; Butler EB; Teh BS
Radiother Oncol; 2018 Nov; 129(2):264-269. PubMed ID: 30031630
[TBL] [Abstract][Full Text] [Related]
13. Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT.
Ogawa Y; Shibamoto Y; Hashizume C; Kondo T; Iwata H; Tomita N; Ogino H
Radiat Oncol; 2018 Jul; 13(1):136. PubMed ID: 30055636
[TBL] [Abstract][Full Text] [Related]
14. Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group.
Ohri N; Werner-Wasik M; Grills IS; Belderbos J; Hope A; Yan D; Kestin LL; Guckenberger M; Sonke JJ; Bissonnette JP; Xiao Y
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e379-84. PubMed ID: 22999272
[TBL] [Abstract][Full Text] [Related]
15. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
16. Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function.
Lu JY; Lin PX; Huang BT
Radiat Oncol; 2019 Jun; 14(1):111. PubMed ID: 31221159
[TBL] [Abstract][Full Text] [Related]
17. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
[TBL] [Abstract][Full Text] [Related]
18. Optimal Radiation Therapy Fractionation Regimens for Early-Stage Non-Small Cell Lung Cancer.
Liu F; Ververs JD; Farris MK; Blackstock AW; Munley MT
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):829-838. PubMed ID: 37734445
[TBL] [Abstract][Full Text] [Related]
19. Altered fractionation schemes in radiotherapy.
Stuschke M; Pöttgen C
Front Radiat Ther Oncol; 2010; 42():150-156. PubMed ID: 19955801
[TBL] [Abstract][Full Text] [Related]
20. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]